RT Journal Article
SR Electronic
T1 Circulating Tumour DNA Analysis Informing Adjuvant Chemotherapy in Stage II Colon Cancer (DYNAMIC Trial): Statistical Analysis Plan
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.09.02.21262816
DO 10.1101/2021.09.02.21262816
A1 Tie, Jeanne
A1 Lo, Serigne N.
A1 Cohen, Joshua D.
A1 Wang, Yuxuan
A1 Wong, Rachel
A1 Shapiro, Jeremy
A1 Harris, Sam
A1 Khattak, Adnan
A1 Burge, Matthew
A1 Vogelstein, Bert
A1 Gibbs, Peter
YR 2021
UL http://medrxiv.org/content/early/2021/09/06/2021.09.02.21262816.abstract
AB Background Detection of circulating tumour DNA (ctDNA) after curative intent treatment reflects the presence of minimal residual disease and predicts for recurrence. DYNAMIC trial is a randomised phase II investigating the clinical utility of ctDNA-guided adjuvant treatment strategy compared with the standard of care (non-ctDNA based) approach in patients with stage II colon cancer. The primary trial endpoint is recurrence-free survival estimated from Kaplan Meier Method at 2 years. Secondary endpoints include proportion of patients treated with adjuvant chemotherapy, time-to-recurrence, overall survival, ctDNA clearance rate (investigational arm) and quality-adjusted life-years.Objective To outline and publish the pre-determined statistical analysis plan (SAP) before the database lock and the start of analysis.Methods The SAP describes basic analysis principles, methods for dealing with a range of commonly encountered data analysis issues and the specific statistical procedures for analysing efficacy and safety outcomes. The SAP was approved after closure of recruitment and before completion of patient follow-up. It outlines the planned primary analyses and a range of subgroup and sensitivity analyses regarding the clinical outcomes. Health economic outcomes are not included in this plan but will be analysed separately. The SAP will be adhered to for the final data analysis of this trial to avoid analysis bias arising from knowledge of the data.Trial Registration ANZ Clinical Trials Registry, ACTRN12615000381583. Registered on 27th April 2015.Competing Interest StatementBV is founder of, and hold equity in Thrive Earlier Detection and Personal Genome Diagnostics. KWK & NP are on the Board of Directors of, and consultants to, Thrive Earlier Detection. BV is consultant to and hold equity in NeoPhore. BV is a consultant to and holds equity in Catalio Capital Management. All other authors declare no competing interests.Clinical TrialACTRN12615000381583Funding StatementThis research is funded by: Australian National Health and Medical Research Council (NHMRC APP1085531); Medical Research Future Fund/NHMRC Investigators Grant (APP1194970)Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Melbourne Health Human and Research Ethics Committee provided approval of the study protocol and patient consent formAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData availability is not applicable for this manuscript